| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Anti-Cancer Powder Nintedanib Ethanesulfonate Salt 656247-18-6 |
| CAS | 656247-18-6 |
| Appearance | White powder |
| Molecular formula | C31H33N5O4.C2H6O3S |
| Molecular Weight | 649.75706 |
| Assay | 98% |
| Shelf Life | 24 months when properly stored |
| Storage | Keep in a cool, dry, dark location |
Nintedanib is the first approved drug for the management of idiopathic pulmonary fibrosis (IPF), a rare but often fatal lung
disease. Nintedanib is believed to exert its mechanism of action by inhibiting multiple receptor tyrosine kinases, including those
that have been implicated in the pathogenesis of IPF (i.e., fibroblast
receptor, and vascular endothelial receptor). Nintedanib also inhibits nonreceptor tyrosine kinases, although the
contribution of this inhibition in the efficacy of the drug is unknown.
Nidanib taesulfonate, the salt form of nidanib, is an angiokinase inhibitor used to treat idiopathic pulmonary fibrosis and also inhibits the formation of blood vessels in a process that can be used as an adjunct to cancer treatment...
Nidanib taesulfonate, the salt form of nidanib, is an angiokinase inhibitor used to treat idiopathic pulmonary fibrosis and also inhibits the formation of blood vessels in a process that can be used as an adjunct to cancer treatment..
){kind=link}